Pregled bibliografske jedinice broj: 630512
Immunomodulatory effects of azithromycin on the establishment of lipopolysaccharide tolerance in mice☆
Immunomodulatory effects of azithromycin on the establishment of lipopolysaccharide tolerance in mice☆ // International immunopharmacology, 15 (2013), 3; 498-504 doi:10.1016/j.intimp.2013.02.011 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 630512 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Immunomodulatory effects of azithromycin on the establishment of lipopolysaccharide tolerance in mice☆
Autori
Bosnar, Martina ; Dominis-Kramarić, Miroslava ; Nujić, Krunoslav ; Stupin Polančec, Darija ; Marjanović, Nikola ; Glojnarić, Ines ; Eraković Haber, Vesna
Izvornik
International immunopharmacology (1567-5769) 15
(2013), 3;
498-504
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
macrolide; survival; sepsis; TNFα; IL-10; IL1ra
Sažetak
Recent reports suggest that azithromycin can shift macrophage polarization towards the alternatively activated M2 phenotype. In order to investigate its immunomodulatory activity in vivo, the influence of azithromycin on survival and cytokine production was assessed in the LPS tolerance model which is characterized by an M2 skewed response. For induction of tolerance, mice received an intraplantar injection of 30 μg LPS, 24 h prior to intravenous challenge with 350 μg LPS. Azithromycin (100 mg/kg) was administered orally, 2 h before LPS application. Influence of treatment on survival and cytokine concentration in serum was monitored. Azithromycin alone, instead of LPS, could not induce an LPS tolerant state. However, when administered before LPS priming it significantly increased survival, which was enhanced by concomitant azithromycin before LPS challenge. Azithromycin had no effect on survival when administered only prior to the LPS challenge. Tolerance induction by LPS priming was associated, upon LPS challenge, with decreased serum concentrations of proinflammatory cytokines, TNFα, IL-12p40 and CCL5, and increased serum concentrations of the anti-inflammatory cytokines, IL-10 and IL-1ra. Azithromycin treatment, prior to LPS priming, further reduced serum TNFα and CCL5, yielding the greatest inhibition when themacrolide was also given prior to LPS challenge. Serum concentrations of the anti-inflammatory cytokines, IL-10 and IL-1ra, were unchanged following azithromycin treatment. In summary, we have confirmed the immunomodulatory activity of azithromycin, as reflected in its ability to augment tolerance induction to LPS, promoting increased survival and reduced pro-inflammatory cytokine production, without affecting overt inflammation to LPS or anti-inflammatory cytokine production.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Fidelta d.o.o.
Profili:
Nikola Marjanović
(autor)
Ines Glojnarić
(autor)
Vesna Eraković Haber
(autor)
Miroslava Dominis-Kramarić
(autor)
Krunoslav Nujić
(autor)
Martina Bosnar
(autor)
Darija Stupin Polančec
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE